Page last updated: 2024-10-21

4-(2-aminoethyl)benzenesulfonylfluoride and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

4-(2-aminoethyl)benzenesulfonylfluoride has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies

Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Magill, L1
Lynas, J1
Morris, TC1
Walker, B1
Irvine, AE1

Other Studies

1 other study available for 4-(2-aminoethyl)benzenesulfonylfluoride and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.
    Haematologica, 2004, Volume: 89, Issue:12

    Topics: Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Edetic Acid; Fusion Proteins, bcr-abl; Hematopoietic

2004